Equities research analysts expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to post earnings of ($0.72) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals posted earnings of ($0.60) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The firm is expected to announce its next earnings results on Monday, March 11th.
According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($3.13) per share for the current fiscal year, with EPS estimates ranging from ($3.18) to ($3.06). For the next financial year, analysts anticipate that the company will report earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.23.
In related news, Director John P. Butler bought 5,000 shares of the stock in a transaction dated Wednesday, August 22nd. The stock was acquired at an average price of $6.43 per share, for a total transaction of $32,150.00. Following the completion of the purchase, the director now owns 5,000 shares in the company, valued at $32,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.67% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of ZYNE. Wells Fargo & Company MN grew its stake in Zynerba Pharmaceuticals by 19.6% during the 1st quarter. Wells Fargo & Company MN now owns 41,414 shares of the company’s stock valued at $360,000 after purchasing an additional 6,782 shares in the last quarter. Northern Trust Corp grew its stake in Zynerba Pharmaceuticals by 17.3% during the 1st quarter. Northern Trust Corp now owns 167,342 shares of the company’s stock valued at $1,455,000 after purchasing an additional 24,663 shares in the last quarter. BlackRock Inc. grew its stake in Zynerba Pharmaceuticals by 5.4% during the 1st quarter. BlackRock Inc. now owns 715,185 shares of the company’s stock valued at $6,216,000 after purchasing an additional 36,488 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Zynerba Pharmaceuticals by 385.6% during the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock valued at $106,000 after purchasing an additional 9,701 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Zynerba Pharmaceuticals during the 1st quarter valued at approximately $903,000. Hedge funds and other institutional investors own 14.08% of the company’s stock.
ZYNE stock opened at $5.95 on Friday. Zynerba Pharmaceuticals has a 1 year low of $5.03 and a 1 year high of $15.14. The stock has a market capitalization of $102.22 million, a PE ratio of -2.40 and a beta of 4.49.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Recommended Story: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.